Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Sanofi Partners With US Army To Push Zika Vaccine Into Clinical Trials



Sanofi is pushing to develop the world’s first Zika vaccine to both provide for the global health crisis, and further strengthen the company’s vaccine portfolio.

Tweetables from this article:

Tweet: The WRAIR will conduct Phase I clinical trial of #Zika vaccine candidate http://ctt.ec/v9UH8+The WRAIR will conduct Phase I clinical trial of Zika vaccine candidate.

Tweet: Sanofi partners with Walter Reed Army Institute of Research for #Zika vaccine http://ctt.ec/ffd3d+Sanofi partners with Walter Reed Army Institute of Research for Zika vaccine.

Share this!

July 7, 2016 | by Sarah Massey, M.Sc.

Global vaccines company Sanofi Pasteur has announced a partnership with the U.S. Army's Walter Reed Army Institute of Research (WRAIR) to co-develop a Zika vaccine candidate. The WRAIR has agreed to transfer its vaccine technology using a purified, inactivated form of the Zika virus, to Sanofi.

In collaboration with multiple government health agencies, the WRAIR will conduct Phase I clinical trials of their Zika vaccine candidate. In return, Sanofi will take responsibility of further development of the vaccine, including conducting Phase II clinical trials, establishing a clinical and regulatory strategy, optimizing production yields and characterizing the vaccine.

Sanofi is just one of multiple companies – including Inovio Pharmaceuticals, GeoVax and Bharat Biotech – in the race to develop a Zika vaccine. Sanofi is pushing to develop the world’s first Zika vaccine to both provide for the global health crisis, and further strengthen the company’s vaccine portfolio.

“We’re looking at this from both a short- and long-term perspective, collaborating to get into the clinic quicker to provide a vaccine in response to the current emergency, and adapting our own technology to ensure production capacity of a vaccine for years to come,” said David Loew, Executive VP and Head of Sanofi Pasteur, in a statement.

According to results from preclinical trials of the WRAIR-developed Zika vaccine – published in the journal, Nature – the candidate showed 100 percent protection against the Zika virus in mice. The authors of the study went on to say that based on these results, “the development of a [Zika] vaccine for humans will likely be readily achievable.”

In addition to the vaccine technology acquired from WRAIR, Sanofi is also leveraging their own platforms to develop a potential Zika vaccine. Sanofi won regulatory approval in late 2015 for its dengue vaccine, which the company hopes might also apply to Zika. The same surface-molecule technology has the potential to work for dengue, Zika and yellow fever, as all three viruses belong to the same flavivirus family.

“In addition to exploring our own vaccine technology used in our new dengue fever vaccine, we are looking at other pathways to get a Zika vaccine into the clinic as soon as possible,” said Loew. “Therefore, this exciting collaboration with the WRAIR creates the opportunity to rapidly move forward.”

So far, Sanofi’s own Zika candidate has not progressed into clinical trials, so it’s possible that they won’t be the first to get a vaccine approval. Last month, competitor company Inovio announced that their Zika vaccine candidate would be entering a Phase I clinical trial in a matter of weeks.

Keywords: Zika, Vaccine, Clinical Trial


Share this with your colleagues!

Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News

FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News

CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.